PH30460A - Peg - interferon conjugates - Google Patents

Peg - interferon conjugates

Info

Publication number
PH30460A
PH30460A PH46719A PH46719A PH30460A PH 30460 A PH30460 A PH 30460A PH 46719 A PH46719 A PH 46719A PH 46719 A PH46719 A PH 46719A PH 30460 A PH30460 A PH 30460A
Authority
PH
Philippines
Prior art keywords
peg
conjugates
interferon conjugates
interferon
polyethylene glycol
Prior art date
Application number
PH46719A
Other languages
English (en)
Inventor
Robert Karasiewicz
Carlo Nalin
Perry Rosen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH30460A publication Critical patent/PH30460A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH46719A 1992-08-26 1993-08-20 Peg - interferon conjugates PH30460A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Publications (1)

Publication Number Publication Date
PH30460A true PH30460A (en) 1997-05-28

Family

ID=25467637

Family Applications (1)

Application Number Title Priority Date Filing Date
PH46719A PH30460A (en) 1992-08-26 1993-08-20 Peg - interferon conjugates

Country Status (37)

Country Link
US (1) US5382657A (lt)
EP (1) EP0593868B1 (lt)
JP (1) JP2859105B2 (lt)
KR (1) KR100295520B1 (lt)
CN (3) CN1039015C (lt)
AT (1) ATE165102T1 (lt)
AU (1) AU668742B2 (lt)
BG (1) BG98067A (lt)
BR (1) BR9303469A (lt)
CA (1) CA2103829C (lt)
CZ (1) CZ169393A3 (lt)
DE (1) DE69317979T2 (lt)
DK (1) DK0593868T3 (lt)
EE (1) EE9400151A (lt)
ES (1) ES2116376T3 (lt)
FI (1) FI109765B (lt)
HR (1) HRP931094A2 (lt)
HU (1) HUT67013A (lt)
IL (1) IL106750A0 (lt)
IS (1) IS4067A (lt)
LT (1) LT3174B (lt)
LV (1) LV10907B (lt)
MW (1) MW7693A1 (lt)
MX (1) MX9305146A (lt)
MY (1) MY131445A (lt)
NO (1) NO933028D0 (lt)
NZ (2) NZ248452A (lt)
OA (1) OA09850A (lt)
PH (1) PH30460A (lt)
PL (1) PL300194A1 (lt)
RO (1) RO112730B1 (lt)
SI (1) SI9300423A (lt)
SK (1) SK89893A3 (lt)
UY (1) UY23635A1 (lt)
YU (1) YU56693A (lt)
ZA (1) ZA936098B (lt)
ZW (1) ZW11193A1 (lt)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7495087B2 (en) * 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
TR200000728T2 (tr) * 1997-09-18 2000-09-21 F.Hoffmann-La Roche Ag Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
HU228877B1 (en) * 1998-03-26 2013-06-28 Merck Sharp & Dohme Formulations for stabilization of peg-interferon alpha conjugates and method for preparation such formulations
DK1421956T3 (da) 1998-04-28 2007-10-01 Applied Research Systems Polyol-IFN-beta-konjugater
TWI277424B (en) 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
EP1079859B1 (en) 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
AU767131B2 (en) * 1998-06-08 2003-10-30 F. Hoffmann-La Roche Ag Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
US6593459B1 (en) * 1998-06-16 2003-07-15 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
EP1656952B1 (en) 1998-10-16 2013-12-18 Biogen Idec MA Inc. Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DK1157037T3 (da) * 1999-01-29 2003-11-24 Hoffmann La Roche GCSF-konjugater
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
PE20010027A1 (es) 1999-04-08 2001-02-05 Schering Corp Uso de interferon alfa pegilado en pacientes con melanoma
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
IL147336A0 (en) 1999-07-07 2002-08-14 Zymogenetics Inc Human cytokine receptor
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1224939A4 (en) 1999-10-12 2005-01-12 Santen Pharmaceutical Co Ltd INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
JP2003534773A (ja) 1999-12-03 2003-11-25 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
EP1251866A1 (en) * 2000-01-24 2002-10-30 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
JP5170931B2 (ja) * 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
ATE432986T1 (de) 2000-11-07 2009-06-15 Zymogenetics Inc Menschlicher rezeptor für tumor necrosis factor
DK1362053T3 (da) * 2001-02-20 2008-03-10 Enzon Inc Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
WO2002070655A2 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2002083166A1 (fr) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Complexes de polymeres d'interferons et leur utilisation medicinale
KR20040030628A (ko) 2001-05-24 2004-04-09 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
WO2003000278A1 (fr) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Onguents
MD2053C2 (ro) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remediu cu acţiune interferonogenă
EP1419191B1 (en) 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR100888371B1 (ko) 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
EP1476181B1 (en) * 2002-01-18 2016-03-23 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
JP4272537B2 (ja) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
EP1496925A4 (en) * 2002-04-11 2007-05-30 Zymogenetics Inc USE OF INTERLEUKIN-24 FOR THE TREATMENT OF OVARIAL CARCINOMA
EP1497415B1 (en) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
CA2491178A1 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
AU2003258518B2 (en) * 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
MXPA05002476A (es) * 2002-09-05 2005-10-19 Gi Company Inc Asialo-interferones modificados y sus usos.
KR20050083678A (ko) * 2002-09-05 2005-08-26 더 제너럴 하스피탈 코포레이션 아시알로-인터페론과 간암의 치료
EP1545623B1 (en) * 2002-09-27 2007-05-09 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
AU2003303635B2 (en) * 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20050089952A1 (en) * 2003-10-22 2005-04-28 Akzo Nobel N.V. Apparatuses and processes for increasing protein PEGylation reaction yields
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) * 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
MXPA06013412A (es) * 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
MXPA06014684A (es) * 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
JP4971160B2 (ja) 2004-08-12 2012-07-11 シェーリング コーポレイション 安定するｐｅｇ化インターフェロン処方物
EP1799713B1 (en) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
ATE541934T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
AU2005322019B2 (en) * 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
AU2006299901A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
CN101242842A (zh) 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
WO2007002233A2 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
EA014157B1 (ru) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
CA2621623A1 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
PT1954710E (pt) * 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
EP2339014B1 (en) * 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
EP1985303B1 (en) 2006-01-12 2012-11-21 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Oral composition containing Interferon-alpha
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
JP5167244B2 (ja) 2006-04-11 2013-03-21 ノバルティス アーゲー Ｈｃｖ／ｈｉｖ阻害剤およびそれらの使用
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
CN101336110B (zh) 2006-06-01 2011-06-01 程云 预防或治疗肝损伤的肽及其衍生物及其应用
CN1911447B (zh) * 2006-06-30 2010-05-12 复旦大学 转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
US8420792B2 (en) * 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
NZ574721A (en) * 2006-09-08 2012-02-24 Ambrx Inc Hybrid suppressor trna for vertebrate cells
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
BRPI0809583B1 (pt) * 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
CA2685596A1 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2196475B1 (en) 2007-09-04 2012-06-06 Biosteed Gene Expression Tech. CO., LTD. INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
PL2186830T3 (pl) 2007-09-04 2012-09-28 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie
ES2629440T5 (es) 2007-10-04 2020-11-20 Zymogenetics Inc zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
NZ603812A (en) * 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
WO2009121210A1 (zh) 2008-04-03 2009-10-08 厦门伯赛基因转录技术有限公司 双链聚乙二醇修饰的生长激素及其制备方法和应用
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
NZ591235A (en) * 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN102458479B (zh) 2009-06-04 2016-07-13 诺华公司 识别IgG结合位点的方法
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
EP2585065A1 (en) 2010-06-24 2013-05-01 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2586296C2 (ru) 2010-07-23 2016-06-10 Демеркс, Инк. Композиции норибогаина
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012045704A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
JP6110791B2 (ja) 2010-11-30 2017-04-05 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2691094A1 (en) 2011-03-31 2014-02-05 Novartis AG Alisporivir to treat hepatitis c virus infection
RU2013148779A (ru) 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
AU2012241859A1 (en) 2011-04-13 2013-10-10 Debiopharm International Sa Treatment of Hepatitis C virus infection with alisporivir
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
WO2013011113A1 (en) 2011-07-20 2013-01-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining treatment response in patients infected with hcv genotype 4
CN103228792A (zh) * 2011-08-25 2013-07-31 纳诺亘医药生物科技公司 PEG-干扰素λ1结合物
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013045460A1 (en) 2011-09-27 2013-04-04 Novartis Ag Alisporivr for treatment of hepatis c virus infection
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
CN104066432B (zh) 2011-12-06 2017-06-13 小利兰·斯坦福大学董事会 用于治疗病毒性疾病的方法和组合物
JP2015500833A (ja) 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
CA2868883C (en) 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
CA2877814A1 (en) 2012-06-22 2013-12-27 Dingqiu HUANG Antigen binding proteins that bind ccr2
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN106535895B (zh) 2014-05-01 2020-02-28 艾格尔峰生物制药有限公司 丁型肝炎病毒感染的治疗
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CA2989550C (en) 2014-06-18 2023-08-08 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
CN107148282A (zh) 2014-08-22 2017-09-08 索伦托治疗有限公司 结合cxcr3的抗原结合蛋白
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
HRP20231732T1 (hr) 2014-11-06 2024-03-15 Pharmaessentia Corporation Režim doziranja pegiliranog interferona
US20180066229A1 (en) * 2015-03-17 2018-03-08 Shinshu University Method for preparing dendritic cells via non-adhesive culture using ifn
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
KR20180073652A (ko) 2015-11-04 2018-07-02 아이거 바이오파마슈티컬스 인코포레이티드 델타 간염 바이러스 감염의 치료
CN116333124A (zh) 2016-01-29 2023-06-27 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
JP7189399B2 (ja) 2017-01-18 2022-12-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
EP3914289A1 (en) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
CN114173784B (zh) 2019-07-18 2023-12-01 埃尼奥制药公司 降低干扰素的副作用的方法
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
AU2021297475A1 (en) 2020-06-22 2023-01-05 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis D Virus infection
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (lt) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (lt) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (lt) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
JPS60127952A (ja) 1983-12-14 1985-07-08 Fanuc Ltd 領域加工方法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JPH04502011A (ja) * 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE300519T1 (de) * 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
ATE136315T1 (de) * 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
JPH04202293A (ja) * 1990-11-29 1992-07-23 Tonen Corp 作動油
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
LTIP888A (lt) 1994-08-25
EP0593868B1 (en) 1998-04-15
EP0593868A1 (en) 1994-04-27
KR100295520B1 (ko) 2001-09-17
CN1039015C (zh) 1998-07-08
JPH06192300A (ja) 1994-07-12
CN1211578A (zh) 1999-03-24
CN1155618C (zh) 2004-06-30
CN1088936A (zh) 1994-07-06
HRP931094A2 (en) 1997-06-30
US5382657A (en) 1995-01-17
DE69317979D1 (de) 1998-05-20
BG98067A (en) 1994-12-02
FI109765B (fi) 2002-10-15
LV10907B (en) 1996-04-20
PL300194A1 (en) 1994-04-05
AU668742B2 (en) 1996-05-16
MW7693A1 (en) 1994-06-08
EE9400151A (et) 1996-02-15
IL106750A0 (en) 1993-12-08
IS4067A (is) 1994-02-27
HUT67013A (en) 1995-01-30
NZ248452A (en) 1995-12-21
LT3174B (en) 1995-02-27
DK0593868T3 (da) 1999-02-08
ATE165102T1 (de) 1998-05-15
BR9303469A (pt) 1994-03-22
JP2859105B2 (ja) 1999-02-17
CA2103829C (en) 2003-04-08
FI933740A0 (fi) 1993-08-25
MX9305146A (es) 1994-03-31
ZA936098B (en) 1994-03-01
KR940003969A (ko) 1994-03-14
NZ264872A (en) 1996-01-26
ZW11193A1 (en) 1994-03-23
CA2103829A1 (en) 1994-02-27
DE69317979T2 (de) 1998-08-20
OA09850A (fr) 1994-08-15
ES2116376T3 (es) 1998-07-16
AU4478093A (en) 1994-03-03
RO112730B1 (ro) 1997-12-30
FI933740A (fi) 1994-02-27
YU56693A (sh) 1997-01-08
NO933028D0 (no) 1993-08-25
CN1183112C (zh) 2005-01-05
SI9300423A (en) 1994-03-31
CZ169393A3 (en) 1994-04-13
MY131445A (en) 2007-08-30
HU9302366D0 (en) 1993-11-29
CN1173500A (zh) 1998-02-18
UY23635A1 (es) 1994-03-01
SK89893A3 (en) 1994-04-06
LV10907A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
ZW11193A1 (en) Peg-interferon conjugates
MC1337A1 (fr) Interferon de fibroblastes humains sous la forme d'une proteine homogene et sa preparation
EP0437026A3 (en) Use of tandospirone in the treatment of depression
FI851365L (fi) Liposomer med inhalerbara allergener foer behandling av allergener, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
EP0468327A3 (en) Oral pharmaceutical compositions containing hirudin
AU109615S (en) Ground engaging element
IL100179A0 (en) The use of carbazones as novel active ingredients in medicaments
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона
BR7002411U (pt) Mesa e quadro conjugados
IT8611845V0 (it) Stazione per il dosaggio e l'immissione di additivi nei mosti.
Taylor The Federal Theatre Project: description of the administration of the FTP and its relationship with the Works Progress Administration
LV5177A3 (lv) Preparats "eridons" govju endometritu profilaksei un arstesanai
ITPD920214A1 (it) Formulazioni per promuovere l'assorbimento vaginale di polipeptidi
AU112487S (en) Folding roof for pantechnicon body
FR2604626B1 (fr) Composition liquide ayant des vertus d'empecher le ronflement
IT9019970A0 (it) Composizioni farmaceutiche ad attivita' riduttrice di radicali ossigeno e loro preparazione
AU103662S (en) Trousers
AU112308S (en) Surfboard
LV5035A3 (lv) Preparats govju endometritu profilaksei un arstesanai
SG168394G (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
SE8802233D0 (sv) Glykoforeningars koppling till markorer och berare